A Phase 1, Open-label, Two-part Study to Investigate the Absorption, Metabolism, and Excretion, and the Absolute Bioavailability of [14C]-LOXO-292 in Healthy Male Subjects
Latest Information Update: 25 Apr 2025
At a glance
- Drugs Selpercatinib (Primary) ; Selpercatinib (Primary)
- Indications CNS cancer; Non-small cell lung cancer; Solid tumours; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 01 Dec 2022 New trial record